Ideaya Biosciences (IDYA) announced that the FDA has agreed to review its new drug application for darovasertib in combination with crizotinib for patients with first line HLA A2-negative metastatic uveal melanoma under the Oncology Center of Excellence Real-Time Oncology Review program.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences price target raised to $58 from $52 at Wedbush
- Ideaya Biosciences price target raised to $54 from $50 at Guggenheim
- Ideaya Biosciences price target raised to $53 from $49 at RBC Capital
- Ideaya Biosciences price target raised to $65 from $60 at Truist
- Ideaya Biosciences rises 22.8%